211 related articles for article (PubMed ID: 21115419)
1. [Gene polymorphisms].
Robert J
Bull Cancer; 2010 Nov; 97(11):1253-64. PubMed ID: 21115419
[TBL] [Abstract][Full Text] [Related]
2. [Towards an inventory of oncogenic mutations in cancer].
Theillet C
Bull Cancer; 2010 Nov; 97(11):1223-9. PubMed ID: 21059490
[TBL] [Abstract][Full Text] [Related]
3. On the use of pharmacogenetics in cancer treatment and clinical trials.
Robert J; Le Morvan V; Giovannetti E; Peters GJ;
Eur J Cancer; 2014 Oct; 50(15):2532-43. PubMed ID: 25103456
[TBL] [Abstract][Full Text] [Related]
4. The role of pharmacogenetics in cancer therapeutics.
Yong WP; Innocenti F; Ratain MJ
Br J Clin Pharmacol; 2006 Jul; 62(1):35-46. PubMed ID: 16842377
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs.
Fabbri M; Croce CM; Calin GA
Cancer J; 2008; 14(1):1-6. PubMed ID: 18303474
[TBL] [Abstract][Full Text] [Related]
6. SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering.
Van den Eynden J; Fierro AC; Verbeke LP; Marchal K
BMC Bioinformatics; 2015 Apr; 16():125. PubMed ID: 25903787
[TBL] [Abstract][Full Text] [Related]
7. Oncogenes and tumor suppressor genes.
Carbone DP
Hosp Pract (Off Ed); 1993 Jun; 28(6):145-8, 153-6, 161. PubMed ID: 8509476
[TBL] [Abstract][Full Text] [Related]
8. Cancer pharmacogenetics.
Marsh S
Methods Mol Biol; 2008; 448():437-46. PubMed ID: 18370241
[TBL] [Abstract][Full Text] [Related]
9. Functional genomics to explore cancer cell vulnerabilities.
Kahle KT; Kozono D; Ng K; Hsieh G; Zinn PO; Nitta M; Chen CC
Neurosurg Focus; 2010 Jan; 28(1):E5. PubMed ID: 20043720
[TBL] [Abstract][Full Text] [Related]
10. [Genetic factors involved in cancer susceptibility].
Kohno T; Yokota J
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1255-62. PubMed ID: 12146010
[TBL] [Abstract][Full Text] [Related]
11. Selection for genome instability by DNA damage in human cells: unstable microsatellites and their consequences for tumourigenesis.
Hampson R
Radiat Oncol Investig; 1997; 5(3):111-4. PubMed ID: 9303066
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacogenetics of anticancer drugs].
de Chaisemartin L; Loriot MA
Pathol Biol (Paris); 2005 Mar; 53(2):116-24. PubMed ID: 15708657
[TBL] [Abstract][Full Text] [Related]
13. Big genes are big mutagen targets: a connection to cancerous, spherical cells?
Parry ML; Ramsamooj M; Blanck G
Cancer Lett; 2015 Jan; 356(2 Pt B):479-82. PubMed ID: 25451318
[TBL] [Abstract][Full Text] [Related]
14. The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.
Petty RD
Clin Oncol (R Coll Radiol); 1996; 8(3):186-9. PubMed ID: 8814375
[No Abstract] [Full Text] [Related]
15. Genome-wide profiling of gene amplification and deletion in cancer.
Kashiwagi H; Uchida K
Hum Cell; 2000 Sep; 13(3):135-41. PubMed ID: 11197775
[TBL] [Abstract][Full Text] [Related]
16. [Discovery and clinical application of mutations in the cancer genome].
Mano H
Nihon Rinsho; 2015 Aug; 73(8):1251-5. PubMed ID: 26281674
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy.
Robert J
J Chemother; 2004 Nov; 16 Suppl 4():22-4. PubMed ID: 15688604
[TBL] [Abstract][Full Text] [Related]
18. [Acquired mutations--basic cancer biology].
Grønbaek K; Guldberg P
Ugeskr Laeger; 2006 Jun; 168(24):2335-8. PubMed ID: 16822414
[TBL] [Abstract][Full Text] [Related]
19. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.
Wang H; Han H; Mousses S; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):513-20. PubMed ID: 16890805
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics for individualized cancer chemotherapy.
Efferth T; Volm M
Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
